CD274 and neoplasm: This suggests an action for PD-1/PD-L1 blockade additional to the promotion of T-cell effector function during T-cell-tumour interactions at the tumour site that is typically considered the key role of PD-1/PD-L1 blockade [22,23] in an anti-tumour setting.